Skip to content
10-Q

Quarterly Report

IMMUNOVANT, INC. IMVT

0001764013-25-000026

← back to feed
Filed
Feb 6, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Jan 31, 2025 169.86M sh
Cash And Equivalents Q3 2025 · Dec 31, 2024 $374.69M
Cash And Equivalents Q3 2025 · Mar 31, 2024 $635.37M
Current Liabilities Q3 2025 · Dec 31, 2024 $68.32M
Current Liabilities Q3 2025 · Mar 31, 2024 $48.61M
Total Liabilities Q3 2025 · Dec 31, 2024 $68.32M
Total Liabilities Q3 2025 · Mar 31, 2024 $48.61M
Current Assets Q3 2025 · Dec 31, 2024 $412.54M
Current Assets Q3 2025 · Mar 31, 2024 $665.77M
Total Assets Q3 2025 · Dec 31, 2024 $420.93M
Total Assets Q3 2025 · Mar 31, 2024 $666.37M
Shares Diluted Q3 2025 · Dec 31, 2023 144.52M sh
Shares Diluted Q3 2025 · Dec 31, 2023 135.58M sh
Capex Q3 2025 · Dec 31, 2023 $210K
Operating Cash Flow Q3 2025 · Dec 31, 2023 −$154.53M
Stockholders Equity Q3 2025 · Dec 31, 2023 $679.34M
Stockholders Equity Q3 2025 · Sep 30, 2023 $251.81M
Stockholders Equity Q3 2025 · Jun 30, 2023 $299.87M
Stockholders Equity Q3 2025 · Mar 31, 2023 $362.49M
Eps Diluted Q3 2025 · Dec 31, 2023 −$0.36
Eps Diluted Q3 2025 · Dec 31, 2023 −$1.36
Eps Basic Q3 2025 · Dec 31, 2023 −$0.36
Eps Basic Q3 2025 · Dec 31, 2023 −$1.36
Sga Expense Q3 2025 · Dec 31, 2023 $13.22M
Sga Expense Q3 2025 · Dec 31, 2023 $42.46M
Net Income Q3 2025 · Dec 31, 2023 −$51.42M
Net Income Q3 2025 · Dec 31, 2023 −$184.02M
Net Income Q3 2025 · Sep 30, 2023 −$58.66M
Net Income Q3 2025 · Jun 30, 2023 −$73.94M